Suresh S. Ramalingam
苏雷什·拉马林加姆
MD, FACP
Executive Director, Winship Cancer Institute; Roberto C. Goizueta Distinguished Chair for Cancer Research; Professor of Hematology and Medical Oncology温希普癌症研究所执行主任，Roberto C. Goizueta杰出癌症研究讲席，血液学与肿瘤内科教授
👥Biography 个人简介
Suresh S. Ramalingam, MD, FACP is Executive Director of the Winship Cancer Institute at Emory University and holds the Roberto C. Goizueta Distinguished Chair for Cancer Research. He is one of the most influential thoracic oncologists in the world, best known for leading the FLAURA trial—the landmark phase III study that established osimertinib as first-line therapy for EGFR-mutant non-small cell lung cancer—but he has also been deeply involved in HNSCC clinical research as part of Emory and the Southeastern Oncology Research Consortium. Dr. Ramalingam's expertise in EGFR-targeted therapy bridges both NSCLC (EGFR kinase-mutant) and HNSCC (EGFR-overexpressing), and he has contributed to studies examining EGFR-directed and immunotherapy-based regimens in HNSCC. As institute director he has championed cross-disease translational research programs and clinical trial infrastructure that support HNSCC alongside thoracic oncology. His contributions to the understanding of EGFR biology, resistance mechanisms, and combination immunotherapy strategies are directly applicable to both lung and head and neck cancer populations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FLAURA Trial — Osimertinib in First-Line EGFR-Mutant NSCLC
Led the FLAURA phase III trial demonstrating that osimertinib, a third-generation EGFR TKI, provided superior progression-free and overall survival compared with gefitinib or erlotinib in first-line EGFR-mutant NSCLC, establishing osimertinib as the global first-line standard and providing an actionable model of EGFR resistance evolution applicable to EGFR-overexpressing HNSCC biology.
EGFR Biology Across HNSCC and NSCLC
Applied understanding of EGFR signaling, resistance mechanisms (T790M in NSCLC, bypass pathway activation in HNSCC), and combination strategy principles across both tumor types, contributing to the conceptual framework for overcoming EGFR inhibitor resistance in squamous carcinomas.
Immunotherapy + Targeted Therapy Combinations at Winship
As Winship Cancer Institute director, led development of clinical trial programs integrating checkpoint immunotherapy with targeted agents in both HNSCC and thoracic malignancies, building cross-disease research collaborations and translational biomarker programs.
HNSCC Clinical Trial Leadership at Emory
Supported and co-led HNSCC clinical trial participation at Winship Cancer Institute through cooperative group mechanisms (ECOG-ACRIN, NRG Oncology), contributing to trials of cetuximab, immunotherapy combinations, and novel targeted approaches in head and neck cancer.
Representative Works 代表性著作
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer (FLAURA)
New England Journal of Medicine (2018)
FLAURA phase III trial establishing osimertinib superior overall survival (38.6 vs 31.8 months) over first-generation EGFR TKIs as first-line therapy for EGFR-mutant advanced NSCLC.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC (FLAURA OS)
New England Journal of Medicine (2020)
Final overall survival analysis of FLAURA confirming osimertinib OS benefit and cementing the standard of care in first-line EGFR-mutant NSCLC.
Mechanisms of Resistance to EGFR Inhibitors in Squamous Cell Carcinomas
Clinical Cancer Research (2014)
Review characterizing shared and distinct EGFR inhibitor resistance mechanisms across NSCLC and HNSCC with implications for combination therapy strategies.
PD-L1 expression as a predictive biomarker for pembrolizumab in squamous cell carcinomas of the lung and head and neck
Journal of Thoracic Oncology (2018)
Cross-disease analysis of PD-L1 expression and checkpoint inhibitor efficacy in squamous carcinomas providing insights applicable to both NSCLC and HNSCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 苏雷什·拉马林加姆 的研究动态
Follow Suresh S. Ramalingam's research updates
留下邮箱，当我们发布与 Suresh S. Ramalingam（Winship Cancer Institute, Emory University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment